Erich A. Leeser

Array ( [id] => 17556026 [patent_doc_number] => 11312702 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof [patent_app_type] => utility [patent_app_number] => 16/997276 [patent_app_country] => US [patent_app_date] => 2020-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 17302 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 385 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932392 [patent_doc_number] => 20210198281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS [patent_app_type] => utility [patent_app_number] => 16/993897 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16993897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18590205 [patent_doc_number] => 11739085 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => Inhibitors of the menin-MLL interaction [patent_app_type] => utility [patent_app_number] => 16/990657 [patent_app_country] => US [patent_app_date] => 2020-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 50143 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16990657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17769334 [patent_doc_number] => 11401259 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 [patent_app_type] => utility [patent_app_number] => 16/987322 [patent_app_country] => US [patent_app_date] => 2020-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20875 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18134706 [patent_doc_number] => 11560359 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression [patent_app_type] => utility [patent_app_number] => 16/984041 [patent_app_country] => US [patent_app_date] => 2020-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 15733 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16984041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18328278 [patent_doc_number] => 11633495 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Compounds and compositions for immunotherapy [patent_app_type] => utility [patent_app_number] => 16/940697 [patent_app_country] => US [patent_app_date] => 2020-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 30578 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 570 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16940697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18071374 [patent_doc_number] => 11530196 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Pyrimidine compound acting on EGFR and ERBB2 [patent_app_type] => utility [patent_app_number] => 17/629844 [patent_app_country] => US [patent_app_date] => 2020-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 12477 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17629844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16539463 [patent_doc_number] => 20200405876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate [patent_app_type] => utility [patent_app_number] => 16/936265 [patent_app_country] => US [patent_app_date] => 2020-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40314 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16936265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18328277 [patent_doc_number] => 11633494 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Compounds and compositions for immunotherapy [patent_app_type] => utility [patent_app_number] => 16/934803 [patent_app_country] => US [patent_app_date] => 2020-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 30579 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 543 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355327 [patent_doc_number] => 20220016123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => PHOSPHOINOSITIDE 3-KINASE AND SRC INHIBITORS FOR TREATMENT OF PANCREATIC CANCER [patent_app_type] => utility [patent_app_number] => 16/932987 [patent_app_country] => US [patent_app_date] => 2020-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16932987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16420704 [patent_doc_number] => 20200345902 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => Rapamycin 40-O-Cyclic Hydrocarbon Esters, Compositions and Methods [patent_app_type] => utility [patent_app_number] => 16/933821 [patent_app_country] => US [patent_app_date] => 2020-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16933821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17784643 [patent_doc_number] => 11407755 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-09 [patent_title] => [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases [patent_app_type] => utility [patent_app_number] => 16/930911 [patent_app_country] => US [patent_app_date] => 2020-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 17826 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16930911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18134707 [patent_doc_number] => 11560360 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Therapeutic compounds [patent_app_type] => utility [patent_app_number] => 16/924763 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 11193 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 309 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16924763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17664103 [patent_doc_number] => 11357779 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => G1T38 superior dosage regimes [patent_app_type] => utility [patent_app_number] => 16/924033 [patent_app_country] => US [patent_app_date] => 2020-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 42 [patent_no_of_words] => 51417 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16924033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16389528 [patent_doc_number] => 20200330469 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => ANIMAL AND HUMAN ANTI-MALARIAL AGENTS [patent_app_type] => utility [patent_app_number] => 16/920752 [patent_app_country] => US [patent_app_date] => 2020-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24391 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16920752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17836354 [patent_doc_number] => 20220273659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/919001 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16919001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17769341 [patent_doc_number] => 11401267 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof [patent_app_type] => utility [patent_app_number] => 16/913949 [patent_app_country] => US [patent_app_date] => 2020-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 77864 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 331 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16913949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17350862 [patent_doc_number] => 11225486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-18 [patent_title] => Tertiary alcohols as PI3K-g inhibitors [patent_app_type] => utility [patent_app_number] => 16/913488 [patent_app_country] => US [patent_app_date] => 2020-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 81915 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 2166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16913488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16360929 [patent_doc_number] => 20200317680 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors [patent_app_type] => utility [patent_app_number] => 16/909686 [patent_app_country] => US [patent_app_date] => 2020-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 2202 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460745 [patent_doc_number] => 10844079 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Spiro aromatic ring compound and application thereof [patent_app_type] => utility [patent_app_number] => 16/908604 [patent_app_country] => US [patent_app_date] => 2020-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25374 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16908604 [rel_patent_id] =>[rel_patent_doc_number] =>)